🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

18 month data from the phase 1b single-arm, open-label clinical trial of AAV-GDNF in #Parkinsons by AskBio Inc. (AskBio) has been published; N=11; Well tolerated & associated with numerical stability (mild cohort; <5 yrs since dx) & improvement (moderate cohort) …mentdisorders.onlinelibrary.wiley.com/doi/10.1002/md…

Future house FutureHouse outlines an end-to-end scientific discovery process with their AI "Robin". Humans are still required for the actual physical experimentation, but the idea/hypothesis generating part is being taken out of our hands: futurehouse.org/research-annou…

"We have to cure this pernicious condition, and we have never been closer to finding a cure." Catch our chairman of the charity’s development board Will Cook discussing our #walkforacure campaign: buff.ly/9ErsB8j

New research provides evidence that PINK1 is a key regulator of immune functions in the gut underlying early stage #Parkinsons-related disease mechanisms; Single-cell RNAseq = peripheral myeloid cells are the earliest highly dysregulated immune cell type nature.com/articles/s4153…

Vidofludimus is an interesting drug - Universität München researchers present the structural & mechanistic profiling of Nurr1 modulation by this agent, enabling structure-guided ligand design of agents that could be useful for #Parkinsons nature.com/articles/s4200…

Gain Therapeutics Gain Therapeutics researchers & collaborators report Gaucher’s fibroblasts (GBA1 variants) have increased Tau accumulation (vs control fibroblasts) & pharmacological enhancement of GCase reversed this effect; Implications for #Parkinsons? nature.com/articles/s4159…

Endurance Bio's announces that their lead agent T-168 (a PGC-1α activator) has been selected for testing on the SLEIPNIR clinical trial platform for #Parkinsons; SLEIPNIR is a multi-arm, "de-risking" platform for rapidly testing new therapies globenewswire.com/news-release/2…

New research from Lukas Goede Andreas Horn & colleagues provides a robust, cross-condition tremor network that may guide both invasive & noninvasive neuromodulation strategies for #Parkinsons & essential tremor nature.com/articles/s4146…

Researchers from LundbeckUS & collaborators present the rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies (#Parkinsons) nature.com/articles/s4153…

Researchers apply NMR spec to quantify metabolites & lipoproteins in #Parkinsons blood from different cohorts to stratify metabolically driven subtypes; ⬆️citrate & dimethylglycine +⬇️creatinine & methionine in early PD vs GBA1 & late PD nature.com/articles/s4159…

Fascinating youtube.com/watch?v=nmdujC…

A personal view on gene therapy for #Parkinsons is a timely & succinct overview of both the progress & challenges - weekend reading! thelancet.com/journals/laneu…

A new interrupted time series analysis (2019–2024) highlights the influence of clinical guidelines on #Parkinsons prescribing practices in the UK, with regional variations suggesting possible demographic or healthcare system factors journals.plos.org/plosone/articl…